Skip to content
About Us
Menu Toggle
Who We Are
Our Leadership
Our Team
Our Board of Directors
Our Scientific Advisors
Our Investors
Science
Menu Toggle
Role of Keratolytics in Ophthalmology
Publications
Programs
Menu Toggle
Our Strategy
R&D Pipeline
Clinical Trials
Patients
News and Events
Menu Toggle
Press Releases
Events
Media
Careers
Main Menu
About Us
Menu Toggle
Who We Are
Our Leadership
Our Team
Our Board of Directors
Our Scientific Advisors
Our Investors
Science
Menu Toggle
Role of Keratolytics in Ophthalmology
Publications
Programs
Menu Toggle
Our Strategy
R&D Pipeline
Clinical Trials
Patients
News and Events
Menu Toggle
Press Releases
Events
Media
Careers
About Us
Menu Toggle
Who We Are
Our Leadership
Our Team
Our Board of Directors
Our Scientific Advisors
Our Investors
Science
Menu Toggle
Role of Keratolytics in Ophthalmology
Publications
Programs
Menu Toggle
Our Strategy
R&D Pipeline
Clinical Trials
Patients
News and Events
Menu Toggle
Press Releases
Events
Media
Careers
Main Menu
About Us
Menu Toggle
Who We Are
Our Leadership
Our Team
Our Board of Directors
Our Scientific Advisors
Our Investors
Science
Menu Toggle
Role of Keratolytics in Ophthalmology
Publications
Programs
Menu Toggle
Our Strategy
R&D Pipeline
Clinical Trials
Patients
News and Events
Menu Toggle
Press Releases
Events
Media
Careers
We’ve set our sights on harnessing the unique properties of keratolytics to revolutionize the treatment of ophthalmic conditions
Delivering First-in-Class
Ophthalmic Keratolytics
About Us
Highly Differentiated Approach Combines Ophthalmologic and Dermatologic Solutions to Harness the Unique Properties of Keratolytics to Treat the Root Cause of Underserved Ocular Indications
Science
Addressing the Full Spectrum of Unmet Patient Needs in Lid Margin and Ocular Surface Diseases
Programs
Latest News
Azura Ophthalmics Announces Participation at the 2023 SVB Securities Global Biopharma Conference
January 17, 2023
Read
Scroll to Top